Rami Manochakian MD, FASCO (@RManochakian) ranks #2 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 84 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: DeLLphi-305, LIBRETTO-432, OptiTROP-Lung06. CMS Open Payments lists $5,503 in 2025 general payments.
At a Glance
- 20 posts naming a trial in 2026
- 18 trials discussed by name
- Lung Cancer: US #2, Global #3 · 84 physicians engaged
- Leading physician voice: #1 of 8 physicians on SOHO-01; #2 of 86 physicians on DeLLphi-305
- CMS Open Payments lists $5,503 in 2025 general payments.
This Month
What Rami Manochakian MD, FASCO has posted in the last 30 days. Updated November 10, 2026.
🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 results of: ⭐️#OptiTROP-#Lung06 phase 3 trial of: ❇️#Sacituzumab Tirumotecan (Sac-TMT)+ #Pembrolizumab Vs #Chemotherapy + #Pembrolizumab 🎯For #1stLine Tx of #PDL1 #negative (PD-L1 < 1%) advanced #NonSquamous non-small-cell #LungCancer (#NSCLC) WITHOUT genomic alterations. Study showed: ‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival Benefit. ✅ #mPFS 15.0 vs 5.7 mo (HR 0.49, p<0.001) ✅#ORR 50.2% and 47.3% ✅Immature #OS data; #HR: 0.49 P<0.001 ✅≥ Grade 3 #AEs: 47.6% vs 60.6% 👇🏻 https://t.co/SbNKX2ZOPm
🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 results of: ⭐️#SAFFRON phase 3 trial of: ❇️#Osimertinib + #Savolitinib (#MET #TKI)! Vs #Chemotherapy (platinum/pemetrexed) 🎯For #2ndLine Tx of #EGFR+ advanced non-small-cell #LungCancer (#NSCLC) with: 🔹#MET #Overexpression or #Amplification or both 🔹#Progression on #Osimertinib Study showed: ‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival (primary endpoint) & #OverallSurvival Benefits. ✅#mPFS: 7.6 vs 5.4 months (HR 0.55) ✅#mOS: 17.8 vs 12.9 months (HR 0.68) ✅ ⚠️ Grade ≥3 AEs: 64% vs 63% 👇🏻 https://t.co/f1xNsvRjhC
🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 results of: ⭐️#KRASCENDO-1 phase 3 trial of: ❇️#Divarasib Vs #Sotorasib/or #Adagrasib 🎯For #PreviouslyTreated #KRAS (#G12C)+ advanced non-small-cell #LungCancer (#NSCLC). Study showed: ‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival (primary endpoint) & #OverallSurvival Benefits. ✅#mPFS: 9.8 vs 5.7 months (HR 0.58) ✅#mOS: 17.7 vs 12.0 months (HR 0.56) ✅#ORR: 58.4% vs 32.3% ✅ ⚠️ Grade ≥3 AEs: 24.6% vs 34.5% 👇🏻 https://t.co/6ggEpQD0vW
🔥🚨@OncoAlert Hot off the press. Just published @Annals_Oncology in conjunction with presentation @myESMO #ESMO26 results of: ⭐️#PERSEE phase 3 trial of: ❇️#Pembrolizumab monotherapy Vs #Pembrolizumab + #Chemotherapy 🎯For #1stLine Tx of advanced non-small-cell #LungCancer (#NSCLC) with HIGH #PDL1 (PD-L1 ≥50%). Study showed: ‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival Benefit. ✅#mPFS: 16.1 vs 6.9 mo (HR 0.56) ❓#mOS: 50.2 vs 29.9 mo NOT Statistical Significant (HR 0.77; 95% CI, 0.56–1.05) Study not powered for #OverallSurvival 👇🏻 https://t.co/V3yc1U84Bi
🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻 https://t.co/JoYBDSUAo9
Who Amplifies Rami Manochakian MD, FASCO
Physicians who reposted Rami Manochakian MD, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #2 | #3 | 84 | 182 | Full ranking |
What Colleagues Are Saying About Rami Manochakian MD, FASCO
2026 posts by fellow physicians that mention @RManochakian, quoted word for word.
Fantastic event w/ @OncBrothers summarizing the major updates from #ASCO26! 🩺🔥 Brilliant insights from an all-star panel on #lungcancer featuring @StephenVLiu, @NarjustFlorezMD, & @RManochakian. Caught up w/ @RManochakian to discuss exciting progress in small cell lung cancer! https://t.co/xYCnaDnsBS
Trials Rami Manochakian MD, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| DeLLphi-305 | 2 | #2 of 86 | Oct 24, 2026 |
| LIBRETTO-432 | 2 | #4 of 53 | May 31, 2026 |
| OptiTROP-Lung06 | 1 | #6 of 29 | Oct 25, 2026 |
| SAFFRON | 1 | #5 of 50 | Oct 25, 2026 |
| KRASCENDO-1 | 1 | #7 of 49 | Oct 25, 2026 |
| PERSEE (GFPC 01-2020) | 1 | #13 of 34 | Oct 25, 2026 |
| ADAURA | 1 | #6 of 41 | Sep 14, 2026 |
| TAISHAN-302 | 1 | #3 of 26 | Sep 13, 2026 |
| MAVERICK (SWOG S1827) | 1 | #26 of 33 | Sep 12, 2026 |
| SOHO-01 | 1 | #1 of 8 | Sep 9, 2026 |
| HARMONi | 1 | #12 of 16 | Aug 25, 2026 |
| KEYNOTE-671 | 1 | #11 of 13 | Aug 21, 2026 |
| ARROS-1 | 1 | #26 of 26 | Jul 22, 2026 |
| DeLLphi-304 | 1 | #13 of 23 | Jun 1, 2026 |
| HARMONi-6 | 1 | #13 of 74 | May 31, 2026 |
| OptiTROP-Lung05 | 1 | #5 of 19 | May 30, 2026 |
| CROWN | 1 | #7 of 36 | May 29, 2026 |
| WU-KONG28 | 1 | #7 of 29 | May 29, 2026 |
Rami Manochakian MD, FASCO on DeLLphi-305
🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻 https://t.co/JoYBDSUAo9
🚨🔥‼️@OncoAlert Hot off the press. #BigNews #PressRelease by @Amgen ⭐️ #DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with Chemo + Durvalumab. Showed: ✅Statistically Significant & Clinically meaningful ⬆️#OverallSurvival (#OS) Benefit. 👇🏻 https://t.co/qOh6UPlvaU
Rami Manochakian MD, FASCO on LIBRETTO-432
🔥🚨@OncoAlert Hot off the press. Just published @NEJM In conjunction with presentation @ASCO #ASCO26. ⭐️Results of #PracticeChanging #LIBRETTO432 Trial of: #Adjuvant #Selpercatinib vs #Placebo in Early-Stage (IB-IIIA) #RET+ Non-Small-Cell #LungCancer. ✅⬆️#EFS ❇️#HR: https://t.co/obSufZ3Urf
🔥🚨@OncoAlert Hot off the press. Just presented @ASCO #ASCO26 (#Plenary Presentation) by Dr. Jonathan Goldman. ⭐️Results of #PracticeChanging #LIBRETTO432 Trial of: #Adjuvant #Selpercatinib vs #Placebo in Early-Stage (IB-IIIA) #RET+ Non-Small-Cell #LungCancer. ✅⬆️#EFS https://t.co/iF0lzjPKlI https://t.co/3YYvsg3s22
Rami Manochakian MD, FASCO on OptiTROP-Lung06
🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 results of: ⭐️#OptiTROP-#Lung06 phase 3 trial of: ❇️#Sacituzumab Tirumotecan (Sac-TMT)+ #Pembrolizumab Vs #Chemotherapy + #Pembrolizumab 🎯For #1stLine Tx of #PDL1 #negative (PD-L1 < 1%) advanced #NonSquamous non-small-cell #LungCancer (#NSCLC) WITHOUT genomic alterations. Study showed: ‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival Benefit. ✅ #mPFS 15.0 vs 5.7 mo (HR 0.49, p<0.001) ✅#ORR 50.2% and 47.3% ✅Immature #OS data; #HR: 0.49 P<0.001 ✅≥ Grade 3 #AEs: 47.6% vs 60.6% 👇🏻 https://t.co/SbNKX2ZOPm
Rami Manochakian MD, FASCO on SAFFRON
🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 results of: ⭐️#SAFFRON phase 3 trial of: ❇️#Osimertinib + #Savolitinib (#MET #TKI)! Vs #Chemotherapy (platinum/pemetrexed) 🎯For #2ndLine Tx of #EGFR+ advanced non-small-cell #LungCancer (#NSCLC) with: 🔹#MET #Overexpression or #Amplification or both 🔹#Progression on #Osimertinib Study showed: ‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival (primary endpoint) & #OverallSurvival Benefits. ✅#mPFS: 7.6 vs 5.4 months (HR 0.55) ✅#mOS: 17.8 vs 12.9 months (HR 0.68) ✅ ⚠️ Grade ≥3 AEs: 64% vs 63% 👇🏻 https://t.co/f1xNsvRjhC
Rami Manochakian MD, FASCO on KRASCENDO-1
🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 results of: ⭐️#KRASCENDO-1 phase 3 trial of: ❇️#Divarasib Vs #Sotorasib/or #Adagrasib 🎯For #PreviouslyTreated #KRAS (#G12C)+ advanced non-small-cell #LungCancer (#NSCLC). Study showed: ‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival (primary endpoint) & #OverallSurvival Benefits. ✅#mPFS: 9.8 vs 5.7 months (HR 0.58) ✅#mOS: 17.7 vs 12.0 months (HR 0.56) ✅#ORR: 58.4% vs 32.3% ✅ ⚠️ Grade ≥3 AEs: 24.6% vs 34.5% 👇🏻 https://t.co/6ggEpQD0vW
Rami Manochakian MD, FASCO on PERSEE (GFPC 01-2020)
🔥🚨@OncoAlert Hot off the press. Just published @Annals_Oncology in conjunction with presentation @myESMO #ESMO26 results of: ⭐️#PERSEE phase 3 trial of: ❇️#Pembrolizumab monotherapy Vs #Pembrolizumab + #Chemotherapy 🎯For #1stLine Tx of advanced non-small-cell #LungCancer (#NSCLC) with HIGH #PDL1 (PD-L1 ≥50%). Study showed: ‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival Benefit. ✅#mPFS: 16.1 vs 6.9 mo (HR 0.56) ❓#mOS: 50.2 vs 29.9 mo NOT Statistical Significant (HR 0.77; 95% CI, 0.56–1.05) Study not powered for #OverallSurvival 👇🏻 https://t.co/V3yc1U84Bi
Rami Manochakian MD, FASCO on ADAURA
🚨🔥@OncoAlert Hot off the press. Just published @JTOonline in conjunction with presentation @IASLC #WCLC26. ⭐️8-Year #OverallSurvival #Update of: ❇️#ADAURA phase 3 trial of #Adjuvant #Osimertinib vs #Placebo for Resected #EGFR mutant Stage IB-IIIA Non-Small Cell #LungCancer. ✅8-y #OS: Stage II-IIIA: 74% vs 58% (HR 0.53) Stage IB-IIIA: 79% vs 64% (HR 0.52) 👇🏻 https://t.co/yYufxv2zhH
Rami Manochakian MD, FASCO on TAISHAN-302
🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @IASLC #WCLC26. ⭐️Results of #TAISHAN302 phase 3 trial of: #Tambotatug pelitecan (B7-H3 #ADC) vs #Topotecan in patients with #SmallCell #LungCancer after progression on 1st line platinum-based therapy. #Impressive results for #Tambotatug pelitecan: ✅⬆️ #mOS: 13.3 vs 9.4 months (#HR: 0.46) ✅⬆️ #mPFS: 7.4 vs 2.8 months (#HR: 0.46) ✅⬆️ #RR: 59.1% vs 9.7% ✅⬇️#Toxicity (≥ grade 3 # AEs: 55.4% vs. 77.9%) 👇🏻 https://t.co/avqw9sYa6v
Rami Manochakian MD, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
🔥🚨@OncoAlert Hot off the press. Just published @NEJM. In conjunction with presentation @myESMO #ELCC26. Results of phase 1 trial of: ⭐️#Setidegrasib in #Patients with #KRAS/#G12D mutant non-small cell #LungCancer & #Pancreas #Cancer. ❇️Adverse Events (#AEs) ≥ 3: 42% ❇️Response Rate (#RR): 36% in #NSCLC 24% in #PancreaticCancer 👇🏻 https://t.co/i6szUj4bOM
📣👏‼️ #BigStory @OncoAlert 🔥🚨Hot Off The Press from #ESMO26 ‼️NOT 1️⃣ NOT 2️⃣ NOT 3️⃣ but rather: ⭐️⭐️⭐️⭐️#FOUR 4️⃣ #Concomitant #Publications on #LungCancer published @NEJM (the world’s #Top #MedicalJournal) in conjunction with GREAT presentations @myESMO #ESMO26 ✅ It’s an Era of GREAT #Research & #EraOfHope for #Patients with #LungCancer 👇🏻🧵Links to #Papers & #Summaries
🚨🔥@OncoAlert Hot off the press. Thank you #ASCODailyNews @ASCO for this article promoting: ⭐️Upcoming #ASCO26 #EducationSession, I’m honored to chair, joined by GREAT Experts: Drs @NReguart & Hegi-Johnson on: ✅#Updates in #SmallCell #LungCancer 👇🏼 https://t.co/yGb6eWRghV https://t.co/tuWyTOkplT https://t.co/y63NEV9uOG
🚨📣Inviting colleagues @ASCO #ASCO26 to: ✅An #EducationSession, I’m honored to chair & speak at, joined by great experts/colleagues: Drs @NReguart & Hegi-Johnson. ⭐️Title: It’s 2026. #Updates in #SmallCell #LungCancer-No Longer Too Small to Ignore. ⏰Sun, May 31st at 8:00 📍Room E451
🚨🔥@OncoAlert HOT OFF THE PRESS. @ASCO Annual Meeting #ASCO26 #Abstracts JUST #RELEASED. Looking forward & ready for: ⭐️GREAT ✅#Science ✅#Research ✅#Education ✅Practice Changing #Studies 🙏It’s an #EraOfHope for #Patients with #Cancer. 👇🏼 https://t.co/xq0SuQK3Fl https://t.co/AOlvn1isLD
Industry Payments
CMS Open Payments · 2025 general payments
$5,503 across 6 payments